Figure 9.
Evaluation of apoA-I nanodiscs efficacy in AD-like condition. (a) The cholesterol efflux was measured using the Cholesterol Efflux Assay kit. After treating the cells with Aβ1-42 oligomers (1 μM or 10 μM) for 24 h, two different cholesterol acceptors, ACM or apoA-I nanodiscs (40 μg/mL), were added. The fluorescence of supernatant and cell lysates was measured by spectrofluorometer. (b) Detection of cell viability, GFAP, and ABCA1 levels to confirm the apoA-I efficacy in restoring some cellular processes related to AD that were compromised by Aβ oligomers; * p <0.05; ** p ≤ 0.01; *** p ≤ 0.001 (one-way ANOVA).